good result I see they i saying looking at more growth options in sth east asia thru transmedic as i highlighted above paragon operates in the same markets be a natural fit with transmedic :eek2: hopefully they look at it
Printable View
ah ebos missed the boat , paragon got a takeover offer last night will be a bigger competitor now for transmedic
yep agree - would expect a TH until they release more info; think it could be read as a sale or an acquisition though? i.e. could be something similar to https://paragoncare.com.au/sites/def...me_2341934.pdf - so PGC shareholders not necessarily going to receive a TO offer?
there it is combined entity will be a 3.5billion company to take on transmedic
anyway i guess it opens up the possibilty of ebos buying the merged entity
still needs a >50% vote in late May, subject to an independent & in absence of a 'superior proposal', so EBO could still gazump last min if they wanted. but yes, most likely is... they look at the larger entity (one day... once the dust settles).
Jeez EBO shareprice down to $33.59 ……lowest since mid 2021
Seems unloved at the moment
Time to buy some?
"Forsyth Barr estimated that a Spark share price of below $4.80 between the 17th and 30th of April would likely trigger the EBOS exit from the ACWI. Funnily enough the Spark share price does indeed slump below that level during that period. We cannot know for sure but if you were running an arbitrage hedge fund a possible trade would be to short sell EBOS now in the expectation of buying it back cheaper when the 9.7 million of index selling hits the market. But to make sure EBOS does leave the index, the arbitrage hedge fund also sells shares in Spark to contribute towards a weaker share price."
https://www.goodreturns.co.nz/articl...or+30+Apr+2024
Interesting. Huge implications if this deal gets scuttled
interesting how pharmacies might have there uber moment and be disrupted
The Chemist Warehouse deal is a sideshow: pharmacies are ripe for bigger disruption
Chemist Warehouse isn’t even Australia’s biggest pharmacy group. That’s EBOS, which runs brands including Terry White, healthSAVE, Cincotta Discount Chemist, Mega Save Chemist, Max Value Pharmacy, BetterBuy Pharmacy, MyMedical Pharmacy and Good Price Pharmacy Warehouse.
https://theconversation.com/the-chem...ruption-232586
https://www.nzx.com/announcements/434580
EBOS and Prime100 Media Speculation
EBOS Group Limited (“EBOS”) notes media commentary (Financial Review – Street Talk, 15 July 2024) speculating on EBOS’ interest in the potential sale of pet food business Prime100.
EBOS advises it will not be participating in any potential forthcoming sale of Prime100.
https://www.nzx.com/announcements/436527
Highlights
• Revenue of $13.2 billion (up 7.8%)
• Underlying EBITDA of $624.3 million (up 7.3%)
• Underlying NPATof $303.4 million (up 7.7%)
• Underlying EPS of 157.9 cents (up 6.8%)
• Final dividend declared of NZ 61.5 cents per share, bringing total dividends declared for theyear to NZ 118.5 cents per share (up 7.7%)
• Continued strong earnings growth in Healthcare and Animal Care segments with HealthcareUnderlying EBITDA up 6.0% and Animal Care Underlying EBITDA up 13.2%
• Significant investments undertaken in line with our strategy of investing for growth, aspreviously announced we increased our shareholding in Transmedic and completed theacquisition of Superior Pet Food Co. (Superior). In addition, we completed four small bolt-onacquisitions in the Medical Technology and Medical Consumables businesses across ANZ andSoutheast Asia1
• ROCE increased by 20 bp to 15.3%, in line with target
• Net Debt : EBITDA reduced to 1.89x compared to 2.06x at December 2023
• To assist investors EBOS is providing guidance for FY25 that the Group expects to generateUnderlying EBITDA of between $575 million to $600 million
Healthcare EBITDA margin 4.3% of sales v Animal 19.4% highlights the value in having the Animal Care segment.
I almost read the last part of your post wrong........
"Our FY25 performance will be impacted by the non-renewal of the CWA contract, which generated approximately $2.2 billion of revenue in FY24 and ceased on 30 June 2024"
Amazed that they anticipate such a minimal reduction in EBITDA in FY24 (guidance only 5% down ) given that significant loss of business. However we all understood it was low margin .....
But they are always looking at ways to grow....
That was my thought too, but will still be showing red arrows on next report which never is a good look. They increasing performance by around 7% now in most key metrics, unlike a few years ago when it tended to be 10-15% per annum. Sold most of mine when the contract loss was announced and stuck it into term deposits, not getting the urge to to start increasing holdings at the moment.